home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

120.29 +2.19 (+1.85%)

Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals ↗

July 22, 2025

MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.

Via Chartmill

Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic ↗

July 21, 2025

Via Stocktwits

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided ↗

July 21, 2025

Via Stocktwits

Does This Move Make Merck Stock a Buy? ↗

July 20, 2025

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? ↗

July 20, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Want Decades of Passive Income? Buy This ETF and Hold It Forever ↗

July 19, 2025

Via The Motley Fool

Topics ETFs Regulatory Compliance Stocks

Merck & Co Unusual Options Activity For July 15 ↗

July 15, 2025

Via Benzinga

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗

July 15, 2025

Via Stocktwits

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 19, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗

July 19, 2025

Via The Motley Fool

Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business ↗

July 17, 2025

Via The Motley Fool

Topics Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

July 16, 2025

Via Benzinga

P/E Ratio Insights for Merck & Co ↗

July 09, 2025

Via Benzinga

1 Dow Jones Stock to Target This Week and 2 to Avoid

July 16, 2025

While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors.

Via StockStory

Topics Stocks

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗

July 15, 2025

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

Via Benzinga

This House of Representative Just Bought Up To $30K In 3M Stock ↗

July 15, 2025

Via Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

July 14, 2025

From Merck & Co., Inc.

Via Business Wire

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial ↗

July 14, 2025

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

Via Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals ↗

July 11, 2025

MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued.

Via Chartmill

2 Top Stocks Down 16% and 17% This Year to Buy and Hold ↗

July 11, 2025

Via The Motley Fool

Topics Intellectual Property

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

July 10, 2025

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

July 10, 2025

From Merck Sharp & Dohme

Via Business Wire

Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps ↗

July 09, 2025

Kazia's early trial data show significant CTC and cluster reduction in a breast cancer patient treated with Paxalisib, Keytruda, and chemotherapy.

Via Benzinga

Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday? ↗

July 09, 2025

Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations.

Via Benzinga

Topics World Trade

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 09, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)

July 09, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug ↗

July 09, 2025

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.

Via Benzinga

Topics Intellectual Property

Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma ↗

July 09, 2025

The takeover target just launched its first drug last summer. Shares have mostly trended higher since.

Via Investor's Business Daily

Topics Government

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com